Suchergebnisse - "Schepisi, Giuseppe"

PubPharm (8)

1

Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer

enthalten in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer | 2020

von Banna, G. | Urzia, V. | Benanti, C. | +10

2

Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer

enthalten in: British journal of cancer | 2020

von Conteduca, V. | Wetterskog, D. | Scarpi, E. | +14

3

Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy

enthalten in: Journal of clinical medicine | 2020

von Conteduca, V. | Caffo, O. | Scarpi, E. | +19

4

Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide

enthalten in: The Prostate | 2019

von Lolli, C. | De Lisi, D. | Conteduca, V. | +11

5

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

enthalten in: European urology | 2019

von Conteduca, V. | Jayaram, A. | Romero-Laorden, N. | +25

6

Association among metabolic syndrome, inflammation, and survival in prostate cancer

enthalten in: Urologic oncology | 2018

von Conteduca, V. | Caffo, O. | Galli, L. | +14

7

Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone

enthalten in: The Prostate | 2017

von Conteduca, V. | Caffo, O. | Lolli, C. | +13

8

Long‐term clinical impact of PSA surge in castration‐resistant prostate cancer patients treated with abiraterone

enthalten in: The prostate | 2017

von Conteduca, V. | Caffo, O. | Lolli, C. | +13

1
[1]